Latest Articles
Absci (NASDAQ: ABSI) prices $100M underwritten equity deal to fund ABS-201 - Stock Titan
Absci (NASDAQ: ABSI) prices $100M underwritten equity deal to fund ABS-201 Stock Titan
Published: June 24, 2026, 8:32 p.m.
Prime Day beauty deals: Save on my favorite products from Solawave, Drybar, and more - Mashable
Prime Day beauty deals: Save on my favorite products from Solawave, Drybar, and more Mashable
Published: June 24, 2026, 7:24 p.m.
Art exhibition gives voice to Rochdale women's experiences of reproductive healthcare - Roch Valley Radio
Art exhibition gives voice to Rochdale women's experiences of reproductive healthcare Roch Valley Radio
Published: June 24, 2026, 3:57 p.m.
Absci prices $100 million stock offering to fund drug programs - Investing.com UK
Absci prices $100 million stock offering to fund drug programs Investing.com UK
Published: June 24, 2026, 2:58 p.m.
Baylen Dupree tears up discussing possible infertility due to endometriosis: ‘Everything is unknown’ (exclusive) - MSN
Baylen Dupree tears up discussing possible infertility due to endometriosis: ‘Everything is unknown’ (exclusive) MSN
Published: June 24, 2026, 2:24 p.m.
Absci surges on Eli Lilly, private equity investments - MSN
Absci surges on Eli Lilly, private equity investments MSN
Published: June 24, 2026, 1:59 p.m.
Absci Raises $100 Million In Equity To Fund AI-Designed Hair Loss And Endometriosis Program - Benzinga
Absci Raises $100 Million In Equity To Fund AI-Designed Hair Loss And Endometriosis Program Benzinga
Published: June 24, 2026, 1:09 p.m.
Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR) - markets.businessinsider.com
Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR) markets.businessinsider.com
Published: June 24, 2026, 11:25 a.m.
Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR) - The Manila Times
Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR) The Manila Times
Published: June 24, 2026, 10:48 a.m.
Absci Reports Positive Phase 1 Results for ABS-201, a First-in-Class PRLR Antibody for Hair Regrowth and Endometriosis – Minichart - Minichart
Absci Reports Positive Phase 1 Results for ABS-201, a First-in-Class PRLR Antibody for Hair Regrowth and Endometriosis – Minichart Minichart
Published: June 24, 2026, 10:45 a.m.
Link copied to clipboard!